STAT3 and cancer: Napabucasin (BBI-608) is being explored as a cancer stem cell inhibitor due to its effects on STAT3 activation as well as on the β-Catenin and Nanog pathways.81–83 Still, the search continues for STAT3 inhibitors that are suitable for clinical use.